NCT03673982 (iCASK) is a NA clinical trial of iCASK in Anorexia Nervosa, sponsored by James Adamson.

Who is sponsoring NCT03673982?

NCT03673982 is sponsored by James Adamson.

What drugs are being tested in NCT03673982?

Interventions in NCT03673982: iCASK.

What condition does NCT03673982 study?

NCT03673982 studies Anorexia Nervosa.

Is NCT03673982 still recruiting?

NCT03673982 is currently completed. Last updated 17 September 2018.

Last reviewed 2018-09-17 · How we verify

NCT03673982: iCASK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carer Skills Training for Inpatients With Anorexia Nervosa (iCASK)

Completed NA Last updated 17 September 2018

What this trial tests

NA trial testing iCASK in Anorexia Nervosa in 31 participants. Completed in 30 August 2018.

Timeline

9 January 2017

Primary endpoint
25 January 2018

30 August 2018

Quick facts

Lead sponsor	James Adamson
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	9 January 2017
Primary completion	25 January 2018
Estimated completion	30 August 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

iCASK

Conditions studied

Anorexia Nervosa — all drugs for Anorexia Nervosa →

Sponsor

James Adamson

Who can join

Adults 17 to 50, female only, with Anorexia Nervosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To improve treatment for patients with severe anorexia nervosa admitted for inpatient care, and to help their families. Inpatients and their families will be offered a novel intervention which includes multimedia training materials. These materials provide guidance in how families can provide support to maintain and build on changes made during inpatient care

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anorexia Nervosa

Currently open trials in the same condition.

NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
NCT07188155 — Adapting Exposure for Adolescent AN · NA · recruiting
NCT07143981 — The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa · recruiting
NCT07311356 — Prognosis of Early-onset Anorexia Nervosa · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03673982 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by James Adamson
Last refreshed: 17 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03673982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing